A multi-center, randomized, double-blind, 52-week study to assess the safety of QVA149 compared to QAB in patients with Chronic Obstructive Pulmonary Disease (COPD) who have moderate to severe airflow limitation
|Effective start/end date||9/1/12 → 12/31/14|
- NOVARTIS PHARMACEUTICALS CORPORATION
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.